MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.
Related to this article
The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.
Advertisement
Advertisement
Trending on AJMC
1
VYD2311 Shows Superior Safety vs mRNA COVID-19 Vaccine
2
Divergent Cost Trends for 3 Advanced Cancers, 2013 vs 2022: A Commercial Claims Analysis
3
Simulating the Impact of the Transforming Episode Accountability Model
4
Unregulated Peptide Side Effects Easy to Miss: Catherine Varney, DO
5